alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2014135EN.01004801.xml

| 5.5.2014 | EN | Official Journal of the European Union | C 135/48 |
| --- | --- | --- | --- |

5.5.2014

EN

Official Journal of the European Union

C 135/48

---

Action brought on 6 February 2014 — Harrys Pubar v OHIM — Harry's New York Bar (HARRY'S NEW YORK BAR)

(Case T-84/14)

2014/C 135/61

Language in which the application was lodged: English

Parties

Parties

Applicant: Harrys Pubar AB (Gothenburg, Sweden) (represented by: L.-E. Ström, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Harry’s New York Bar SA (Paris, France)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 14 November 2013 given in Joined Cases R 1038/2012-1 and R 1045/2012-1; |
| --- | --- |

—

Annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 14 November 2013 given in Joined Cases R 1038/2012-1 and R 1045/2012-1;

| — | Order the defendant to pay the costs of proceedings. |
| --- | --- |

—

Order the defendant to pay the costs of proceedings.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The other party to the proceedings before the Board of Appeal

Applicant for a Community trade mark:

Community trade mark concerned: The word mark ‘HARRY’S NEW YORK BAR’ for goods and services in Classes 25, 30, 32 and 43 — Community trade mark application No 3 383 445

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: The applicant

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: Swedish trade mark registrations Nos 356 009, 320 026, 315 142, 55 6513-1066 for goods and services in Classes 25 and 42

Mark or sign cited in opposition:

Decision of the Opposition Division: Allowed the opposition in part

Decision of the Opposition Division:

Decision of the Board of Appeal: Upheld the appeal in part in Case R 1038/2012-1 and dismissed the appeal in Case R 1045/2012-1

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8(1)(b) and 4 CTMR.

Pleas in law:

---
UNPUBLISHED UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT No. 06-6608 STANFORD EL CHRISTOPHER MCPHERSON, JR., a/k/a Chris Rattis, Plaintiff - Appellant, versus JOI CRYSTAL NORFLEET; ERROL DAWSON JARMAN, Agent, “S.B.I”; SCOTT DAVID SIKKINK, Det.; TABITHA ANN ADKINS, Defendants - Appellees. Appeal from the United States District Court for the Eastern District of North Carolina, at Raleigh. Malcolm J. Howard, Senior District Judge. (5:04-ct-00713-H) Submitted: August 24, 2006 Decided: August 30, 2006 Before KING, SHEDD, and DUNCAN, Circuit Judges. Affirmed by unpublished per curiam opinion. Stanford El Christopher McPherson, Jr., Appellant Pro Se. Unpublished opinions are not binding precedent in this circuit. See Local Rule 36(c).- 2 - PER CURIAM: Stanford El Christopher McPherson, Jr., appeals the district court’s order denying his attempt to file motions in his 42 U.S.C. § 1983 (2000) complaint that had been dismissed in 2004. We have reviewed the record and find no reversible error. Accordingly, we affirm for the reasons stated by the district court. McPherson v. Norfleet, No. 5:04-ct-00713-H (E.D.N.C. filed Mar. 28, 2006 & entered Mar. 29, 2006). We deny McPherson’s motion for appointment of counsel and dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

AFFIRMED
§ 520.1720a Phenylbutazone tablets and boluses. ( a ) *Specifications.* Each tablet contains 100, 200, or 400 milligrams (mg), or 1 gram (g) phenylbutazone. Each bolus contains 1, 2, or 4 g phenylbutazone.
( b ) *Sponsors.* See sponsor numbers in § 510.600(c) of this chapter, as follows: ( 1 ) No. 000061 for use of 100- or 400-mg or 1-g tablets, or 2- or 4-g boluses, in dogs and horses.
( 2 ) No. 069043 for use of 100- or 200-mg or 1-g tablets in dogs and horses.
( 3 ) Nos. 054771 and 061133 for use of 100-mg or 1-g tablets in dogs and horses.
( 4 ) No. 058829 for use of 100-mg or 1-g tablets in dogs and horses.
( 5 ) No. 058198 for use of 1-g tablets in horses.
( c ) *Conditions of use* — ( 1 ) *Dogs* — ( i ) *Amount.* 20 mg per pound of body weight daily.
( ii ) *Indications for use.* For the relief of inflammatory conditions associated with the musculoskeletal system.
( iii ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
( 2 ) *Horses* — ( i ) *Amount.* 1 to 2 g per 500 pounds of body weight daily.
( ii ) *Indications for use.* For the relief of inflammatory conditions associated with the musculoskeletal system.
( iii ) *Limitations.* Do not use in horses intended for human consumption. Federal law prohibits the use of this drug in female dairy cattle 20 months of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[73 FR 8192, Feb. 13, 2008, as amended at 74 FR 1146, Jan. 12, 2009; 76 FR 11331, Mar. 2, 2011; 76 FR 17777, Mar. 31, 2011; 78 FR 21060, Apr. 9, 2013; 78 FR 28826, May 20, 2014; 81 FR 17607, Mar. 30, 2016; 83 FR 48946, Sept. 28, 2018; 84 FR 8973, Mar. 13, 2019; 85 FR 45307, July 28, 2020; 86 FR 14819, Mar. 19, 2021; 87 FR 58961, Sept. 29, 2022]
**Exhibit 31.2**

 

**CERTIFICATION**

 

I, Richard J. Baum, certifythat:

 

1. I have reviewed thisquarterly report on Form 10-Q of Ebix, Inc.;

 

2. Based on my knowledge, thisreport does not contain any untrue statement of a material fact or omit tostate a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading withrespect to the period covered by this report;

 

3. Based on my knowledge, thefinancial statements, and other financial information included in this report,fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periodspresented in this report;

 

4. The registrant’s othercertifying officer and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

 

(a) Designed such disclosurecontrols and procedures, or caused such disclosure controls and procedures tobe designed under our supervision, to ensure that material information relatingto the registrant, including its consolidated subsidiaries, is made known to usby others within those entities, particularly during the period in which thisreport is being prepared;

 

(b) Evaluated the effectivenessof the registrant’s disclosure controls and procedures and presented in thisreport our conclusions about the effectiveness of the disclosure controls andprocedures, as of the end of the period covered by this report based on suchevaluation; and

 

(c) Disclosed in this reportany change in the registrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter (the registrant’sfourth fiscal quarter in the case of an annual report) that has materiallyaffected, or is reasonably likely to materially affect, the registrant’sinternal control over financial reporting; and

 

5. The registrant’s othercertifying officer and I have disclosed, based on our most recent evaluation ofinternal control over financial reporting, to the registrant’s auditors and theaudit committee of the registrant’s board of directors (or persons performingthe equivalent functions):

 

(a) All significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and reportfinancial information; and

 

(b) Any fraud, whether or notmaterial, that involves management or other employees who have a significantrole in the registrant’s internal control over financial reporting.

 

 
| Date:  | May 17, 2004            | /s/ Richard J. Baum |   |
|--------|-------------------------|---------------------|--------|
|   | Richard J. Baum         |
|   | Chief Financial Officer |

 

1

----
<PAGE>
                                                                   EXHIBIT 10.27
                               SECOND AMENDMENT TO

                          M/I SCHOTTENSTEIN HOMES, INC.

                       DIRECTOR DEFERRED COMPENSATION PLAN


WHEREAS, in 1997, M/I Schottenstein Homes, Inc. ("Company") adopted the M/I
Schottenstein Homes, Inc. Director Deferred Compensation Plan ("Plan") to
provide its Directors with an opportunity to defer all or a portion of their
Eligible Compensation and to invest in the Company's Common Shares;

WHEREAS, the Company also retained in Section 10 of the Plan the right to amend
the Plan at any time;

NOW, THEREFORE, effective July 1, 2001:

     1.   Plan Section 5.A is amended to read, in its entirety, as follows:

          Time of Payment. Distribution of a Participant's Deferred Compensation
          Account shall be made on or about the 50th day, but in no event later
          than the 60th day, after the earlier of (i) the date specified by the
          Participant in the Deferral Notice delivered to the Plan Administrator
          at the time the deferral election is made; or (ii) the date of the
          Participant's termination of service as a Director due to resignation,
          retirement, death or otherwise.

     2.   The Deferral Notice attached to the Plan as an exhibit shall be
          replaced by the Deferral Notice attached to this Amendment.

          IN WITNESS WHEREOF, the Company has caused this Amendment to be
     executed by a duly authorized officer.

                                             M/I SCHOTTENSTEIN HOMES, INC.



                                             By:________________________________


                                             Its:_______________________________
                                                       Name (Please Print)
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1080 Androsterone test system. ( a ) *Identification.* An androsterone test system is a device intended to measure the hormone adrosterone in serum, plasma, and urine. Androsterone measurements are used in the diagnosis and treatment of gonadal and adrenal diseases.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2305, Jan. 14, 2000]
**Exhibit32.2**

**CERTIFICATIONPURSUANT TO****18 U.S.C. SECTION 1350,****AS ADOPTED PURSUANT TO****SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with theQuarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for the periodended September 30, 2007 as filed with the Securities and Exchange Commissionon the date hereof (the “Report”), I, Robert Kerris, Chief Financial Officer ofthe Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 ofthe Sarbanes-Oxley Act of 2002, that:

1. The Report fullycomplies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and

2. The informationcontained in the Report fairly presents, in all material respects, thefinancial condition and results of operations of the Company.
| By:          /s/  Robert Kerris |   |
|------------------------------------------------------------------------------|--------|
|                                                                         |
| Name:    Robert  Kerris                                       |
|                                                                         |
| Chief Financial Officer & Principal Accounting  Officer                  |
|                                                                         |
| October 31, 2007                                                             |

 

 

----
Ninth Amendment to Services Agreement with Kathy Bronstein


EXHIBIT 10.3.10 
 
NINTH AMENDMENT TO 
SERVICES AGREEMENT 
 
THIS AMENDMENT (“Amendment”) is made and entered into this 4th day of April,
2002, by and between THE WET SEAL, INC., a Delaware corporation (The “Company”), and KATHY BRONSTEIN (the “Bronstein”). 
 
WITNESSETH: 
 
WHEREAS, the parties entered into a Services Agreement as of December 30, 1988, Amendments thereto dated June, 1990, March 23, 1992,
November 17, 1994, January 14, 1995, January 30, 1995, February 2, 1996, February 4, 2001 and the Supplemental Compensation Agreement dated April 1, 2001 and the Termination of Supplemental Compensation Agreement dated April 2, 2002 (all such
documents referred herein as the “Services Agreement”); 
 
WHEREAS, the Board of Directors and Compensation Committee have approved the increase of Executive’s Basic Salary as set forth below; and 
 
WHEREAS, the parties named above desire to supplement and amend certain terms of the Services Agreement.

 
NOW, THEREFORE, in consideration of the
foregoing premises and for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, the parties agree as follows: 
 
1. Capitalized Terms. Except as otherwise provided herein, capitalized terms used but not defined herein shall have the same
meanings ascribed to them in the Services Agreement. 
 
2. Amendments. The Services Agreement is hereby amended as follows: 
 

	 	(A)	 	From and after February 4, 2002, Bronstein’s Basic Salary shall be Eight Hundred Thousand Dollars ($800,000) per annum, payable semimonthly.


 

	 	(B)	 	There shall be no further increases of the Basic Salary, the Allowance percentage and the Profit Adjustment (each as amended) for a period of four years through
February 3, 2006, irrespective of the duration of Bronstein’s employment. 

 
Except as amended here herein, the Services Agreement as amended is hereby confirmed and republished in full and acknowledged by the parties to be in full force and affect. 






 
The parties
hereto have executed this Amendment as of the day and year first written above. 
 

	 THE WET SEAL, INC.
(“Company”)
	 	 	 	 Kathy Bronstein (“Bronstein”)


 

	
	 /s/    WALTER
LOEB        

	 	 	 	 /s/    KATHY
BRONSTEIN        


	 Walter Loeb
 Chairman of the Compensation Committee
	 	 	 	 Kathy Bronstein
**Exhibit 23.1**
**CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS**
        As independent public accountants, we hereby consent to the incorporationof our reports dated March 30, 2001, included on pages F-2 and S-1 of the 2000Annual Report to Shareholders on Form 10-K/A of UroCor, Inc., into thepreviously filed Registration Statements on Form S-8 (File No. 333-16075,333-58013, 333-58015 and 333-58017, 333-44716, 333-44718) of UroCor, Inc.
        ARTHUR ANDERSEN LLP
Oklahoma City, Oklahoma,
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7653 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7653

 To amend title 38, United States Code, to update certain terminology 
                     regarding veteran employment.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 13, 2024

Mr. Davis of North Carolina (for himself and Mr. Ciscomani) introduced 
 the following bill; which was referred to the Committee on Veterans' 
                                Affairs

_______________________________________________________________________

                                 A BILL

 
 To amend title 38, United States Code, to update certain terminology 
                     regarding veteran employment.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Veterans Employment Readiness Yield 
Act of 2024'' or the ``VERY Act of 2024''.

SEC. 2. UPDATE OF CERTAIN TERMINOLOGY REGARDING VETERAN EMPLOYMENT.

    Title 38, United States Code, is amended--
            (1) by striking ``employment handicap'' each place it 
        occurs and inserting ``employment barrier''; and
            (2) by striking ``employment handicaps'' each place it 
        occurs and inserting ``employment barriers''.
                                 <all>
```
<PAGE>   1
                                                                    EXHIBIT 23.1

                    CONSENT OF INDEPENDENT PUBLIC ACCOUNTANTS

As independent public accountants, we hereby consent to the incorporation of our
report dated April 12, 2001, (except with respect to the matter discussed in
the fourth paragraph of Note 19, as to which the date is April 16, 2001), and
our report dated April 16, 2001, included in this Form 10-K, into the Company's
previously filed Registration Statements on Form S-8 File Nos. 33-98116,
333-09083, 333-09087, 333-30114, and 333-36890 and on Form S-3 File Nos.
333-18313 and 333-49306.

                                    ARTHUR ANDERSEN LLP

Dallas, Texas
April 16, 2001
# C_2016260EN.01003901.xml

| 18.7.2016 | EN | Official Journal of the European Union | C 260/39 |
| --- | --- | --- | --- |

18.7.2016

EN

Official Journal of the European Union

C 260/39

---

Order of the General Court of 25 May 2016 — Stagecoach Group v EUIPO (MEGABUS.COM)

(Case T-805/14) (1)

1

((European Union trade mark - Application for a European Union word mark MEGABUS.COM - Absolute grounds for refusal - Lack of distinctive character - Article 7(1)(b) of Regulation (EC) No 207/2009 - Descriptive character - Article 7(1)(c) of Regulation No 207/2009 - Article 7(3) of Regulation No 207/2009 - Article 75 of Regulation No 207/2009 - Action manifestly inadmissible and manifestly lacking any foundation in law))

(2016/C 260/48)

Language of the case: English

Parties

Parties

Applicant: Stagecoach Group plc (Perth, United Kingdom) (represented by: G. Jacobs, lawyer)

Applicant:

Defendant: European Union Intellectual Property Office (represented by: L. Rampini, acting as Agent)

Defendant:

Re:

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 7 October 2014 (Case R 1894/2013-4) concerning an application for registration of the word sign MEGABUS.COM as a European Union trade mark.

Operative part of the order

Operative part of the order

| 1. | The action is dismissed as being in part manifestly inadmissible and in part manifestly lacking any foundation in law. |
| --- | --- |

1.

The action is dismissed as being in part manifestly inadmissible and in part manifestly lacking any foundation in law.

| 2. | Stagecoach Group plc shall pay the costs. |
| --- | --- |

2.

Stagecoach Group plc shall pay the costs.

---

(1)  OJ C 34, 2.2.2015.

1

---
**Exhibit 31.1**

 

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

 

I, Thomas J. Shaw, certify that: 

 

1. I have reviewed this annual report on Form 10KSB-A2 of Retractable Technologies, Inc.; 

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary tomake the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financialcondition, results of operations, and cash flows of the small business issuer as of, and for, the periods presented in this report; 

 

4. The small business issuer’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e) for the small business issuer and have: 

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including itsconsolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

 

b) Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectivenessof the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; 

 

c) Disclosed in this report any changes in the small business issuer’s internal controls over financial reporting that occurred during the small businessissuer’s most recent fiscal quarter (the small business issuer’s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal controlsover financial reporting; and 

 

5. The small business issuer’s othercertifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors(or persons performing the equivalent functions): 

 

a) All significantdeficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize, and report financialinformation; and 

 

b) Any fraud, whether or not material, that involvesmanagement or other employees who have a significant role in the small business issuer’s internal controls over financial reporting. 

 

Date:     September 24, 2004